Having financed the group without interruption since its spin-off from the Sanofi group in 1999, EMZ participates in the 4th LBO on the group.
The Management of Ceva, majority shareholder of the group, reorganised its capital structure while retaining the control of the group. The new capital structure paves the way to the entry of Temasek, Singaporean sovereign fund and CDH Investments, a Chinese investment fund.
EMZ, who had invested in the successive LBO transactions on the group since it went independent (1999, 2003, 2007), participates in the new operation through funds EMZ 6 and EMZ 7.
This transaction will support Ceva’s ambition to become the first independent player within the top 5 global animal health companies by 2020. Ceva is currently the 9th largest animal health company, and posted sales of nearly €700 million in 2013.
